{"product_id":"cjc-1295","title":"CJC-1295","description":"\u003ch2\u003e\u003cspan\u003eCJC-1295 – Long-Acting GHRH Research Peptide\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cspan\u003eGrowth Hormone-Releasing Hormone Analogue for Pituitary Signaling, GH Secretion \u0026amp; IGF-1 Research\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCJC-1295\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e is a synthetic, long-acting analogue of \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eGrowth Hormone-Releasing Hormone (GHRH)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e developed for scientific investigation of pituitary growth hormone secretion, endocrine signaling and the growth hormone–insulin-like growth factor 1 (GH–IGF-1) axis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 was designed using a modified GHRH peptide sequence combined with a \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eDrug Affinity Complex (DAC)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e that enables prolonged association with circulating albumin.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis molecular design distinguishes the original CJC-1295 compound from shorter-acting GHRH analogues.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe prolonged pharmacokinetic profile of CJC-1295 has made it an important investigational peptide in studies involving:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eGrowth hormone-releasing hormone receptor signaling\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003ePituitary endocrine function\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eGrowth hormone secretion\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eIGF-1 regulation\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eHormonal pulsatility\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003ePeptide pharmacokinetics\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eAlbumin-binding peptide technology\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eNeuroendocrine physiology\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eEarly human clinical studies demonstrated sustained changes in circulating growth hormone and IGF-1 concentrations following administration of investigational CJC-1295 formulations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, these findings do not establish CJC-1295 as a clinically effective or approved treatment for muscle growth, fat loss, recovery, longevity or general hormonal optimization.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eICAME Pharmacy CJC-1295 is intended strictly for laboratory research and development purposes. It is not intended for human or veterinary use.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eWhat Is CJC-1295?\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 is a modified peptide analogue of the biologically active N-terminal region of human growth hormone-releasing hormone.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNatural GHRH is produced primarily by neurons in the hypothalamus.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts principal physiological function is to stimulate the anterior pituitary gland to release growth hormone.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eGrowth hormone subsequently influences multiple tissues and contributes to the regulation of IGF-1 production.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 was developed to investigate whether structural modification of a GHRH-derived peptide could extend its duration of activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe original compound incorporates a drug affinity complex designed to interact with circulating albumin, increasing systemic exposure compared with short-acting GHRH-derived peptides.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis makes CJC-1295 relevant to research involving both endocrine physiology and long-acting peptide design.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 and Growth Hormone-Releasing Hormone\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGrowth Hormone-Releasing Hormone (GHRH)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e is an endogenous hypothalamic peptide hormone.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt acts on specialized cells in the anterior pituitary gland known as somatotrophs.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eGHRH binds to the \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eGHRH receptor (GHRHR)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, a G protein-coupled receptor involved in regulating growth hormone secretion.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe physiological pathway can be summarized as follows:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eHypothalamus\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e↓\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGHRH Release\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e↓\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGHRH Receptor Activation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e↓\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAnterior Pituitary Somatotrophs\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e↓\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGrowth Hormone Secretion\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e↓\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIGF-1 Production and Endocrine Signaling\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis system is regulated by additional factors, including somatostatin, ghrelin-associated signaling and feedback from growth hormone and IGF-1.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 has been investigated as an experimental means of prolonging stimulation of this endocrine pathway.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eHow Does CJC-1295 Work?\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 acts as a GHRH receptor agonist.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe peptide interacts with GHRH receptors expressed by pituitary somatotrophs.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eActivation of these receptors stimulates intracellular signaling pathways associated with growth hormone secretion.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe GHRH receptor primarily couples to \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eGs proteins\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, which stimulate adenylyl cyclase activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis increases intracellular cyclic adenosine monophosphate (cAMP) and activates downstream signaling mechanisms.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eSimplified Mechanism of Action\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCJC-1295\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e↓\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGHRH Receptor (GHRHR)\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e↓\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGs Protein Activation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e↓\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAdenylyl Cyclase\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e↓\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIncreased cAMP Signaling\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e↓\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eProtein Kinase A-Associated Pathways\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e↓\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePituitary Growth Hormone Secretion\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e↓\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGH–IGF-1 Axis Signaling\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe activity of this pathway depends on the physiological condition of the pituitary gland and the broader endocrine regulatory environment.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 does not replace growth hormone itself; it is designed to stimulate endogenous hormone secretion through GHRH-associated signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eWhat Is the Drug Affinity Complex (DAC)?\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eThe \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eDrug Affinity Complex (DAC)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e is one of the defining structural features of the original CJC-1295 molecule.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt was developed to extend the circulating duration of peptide activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eConventional peptide hormones are often cleared rapidly because of enzymatic degradation and renal elimination.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe DAC component of CJC-1295 contains a reactive chemical group designed to form a covalent bond with circulating albumin.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAlbumin is a major plasma protein that contributes to the transport and distribution of numerous endogenous and pharmaceutical molecules.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBy associating with albumin, CJC-1295 exhibits a substantially prolonged pharmacokinetic profile.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Significance of DAC Technology\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAlbumin association\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eExtended systemic exposure\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eReduced rapid peptide clearance\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eProlonged receptor-associated activity\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eLong-acting peptide pharmacology\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePeptide–protein conjugation research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe albumin-binding design of CJC-1295 has made it relevant to the broader development of long-acting peptide technologies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 With DAC vs. Without DAC\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eA critical distinction in CJC-1295 research is the difference between the original albumin-binding compound and products marketed as CJC-1295 without DAC.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe latter are commonly associated with \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eModified GRF (1–29)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, a related but chemically distinct GHRH analogue.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese compounds should not be treated as interchangeable.\u003c\/span\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003e\u003cspan\u003eCharacteristic\u003c\/span\u003e\u003c\/th\u003e\n\u003cth\u003e\u003cspan\u003eCJC-1295 With DAC\u003c\/span\u003e\u003c\/th\u003e\n\u003cth\u003e\u003cspan\u003eModified GRF (1–29), Often Called No DAC\u003c\/span\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003eMolecular classification\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eModified GHRH analogue with DAC\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eModified GHRH analogue\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003eAlbumin-binding DAC\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003ePresent\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eAbsent\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003eLong-acting albumin association\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eDesigned and demonstrated\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eNot applicable\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003ePublished human pharmacokinetic studies\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eAvailable\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eNot established by original CJC-1295 trials\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003eMulti-day half-life\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eReported\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eCannot be inferred from DAC studies\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003eGH\/IGF-1 human study results\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eReported\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eNot established by DAC-form studies\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cspan\u003eThe original published CJC-1295 clinical studies investigated the long-acting DAC-containing molecule.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThose results should not automatically be applied to Modified GRF (1–29).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAccurate product identification is therefore essential for scientific documentation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 and Growth Hormone Secretion\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eGrowth hormone is secreted by the anterior pituitary gland.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts secretion is regulated by hypothalamic hormones, metabolic conditions, sleep-related physiology and endocrine feedback mechanisms.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 has been investigated for its ability to stimulate endogenous growth hormone secretion over a prolonged period.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eEarly clinical studies in healthy adults demonstrated sustained increases in circulating growth hormone concentrations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese findings provided evidence that prolonged GHRH receptor stimulation could influence the GH–IGF-1 endocrine axis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, increased circulating growth hormone is a pharmacodynamic finding.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt does not independently establish improvements in strength, physical performance, body composition or health outcomes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 and IGF-1 Research\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eInsulin-Like Growth Factor 1 (IGF-1)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e is an important mediator of growth hormone-associated endocrine signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eGrowth hormone stimulates IGF-1 production in several tissues, particularly the liver.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIGF-1 participates in biological processes associated with growth, cellular signaling and metabolic regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 research has examined how prolonged GHRH receptor activation influences circulating IGF-1 concentrations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInvestigated pathways include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGH-dependent IGF-1 production\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEndocrine feedback regulation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIGF-1-associated cellular signaling\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePituitary–hepatic communication\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eHormonal response duration\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eNeuroendocrine adaptation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe GH–IGF-1 axis is biologically complex, and sustained changes in hormone concentrations may have both physiological and safety implications.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 and Hormonal Pulsatility\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eGrowth hormone is normally released in pulses rather than at a constant rate.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis pulsatile secretion is an important feature of normal endocrine physiology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eGH pulses are influenced by the interaction between GHRH, somatostatin and other regulatory factors.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOne concern associated with prolonged stimulation of the GHRH receptor is whether it alters the normal pattern of GH secretion.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eA published human study investigated this question following exposure to CJC-1295.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe researchers observed increased growth hormone secretion while the pulsatile pattern was preserved.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe findings suggested that continuous GHRH receptor stimulation could increase baseline GH secretion without completely eliminating normal secretory pulsatility.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis makes CJC-1295 particularly relevant to research examining the relationship between hormone secretion patterns and sustained receptor activation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eHuman Clinical Research on CJC-1295\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eA study published in the \u003c\/span\u003e\u003cem\u003e\u003cspan\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/span\u003e\u003c\/em\u003e\u003cspan\u003e in 2006 evaluated the pharmacokinetics, pharmacodynamic activity and short-term safety of CJC-1295 in healthy adults.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe investigation included randomized, placebo-controlled, double-blind studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eParticipants were monitored for changes in circulating growth hormone and IGF-1 concentrations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFollowing a single administration of the investigational DAC-containing formulation, researchers reported:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGrowth Hormone:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Mean plasma concentrations increased approximately 2- to 10-fold for six days or longer.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIGF-1:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Mean plasma concentrations increased approximately 1.5- to 3-fold for nine to eleven days.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEstimated Half-Life:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Approximately 5.8–8.1 days.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese findings demonstrated prolonged endocrine activity in the investigated population.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, the trials were relatively small and focused primarily on hormonal biomarkers and short-term pharmacological outcomes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThey did not establish long-term clinical efficacy or safety for general human use.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 and Pituitary Function Research\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eThe anterior pituitary gland is a central component of the endocrine system.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts somatotroph cells produce and release growth hormone in response to multiple physiological signals.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 research is relevant to understanding:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eGHRH receptor activation\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eSomatotroph signaling\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003ecAMP-dependent pathways\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eGrowth hormone secretion\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eEndocrine feedback\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eHormonal pulsatility\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003ePituitary responsiveness\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eLong-acting receptor stimulation\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThese pathways are important in the study of neuroendocrine regulation and growth hormone physiology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 and Peptide Pharmacokinetics\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003ePharmacokinetics describes how a substance is absorbed, distributed, metabolized and eliminated.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePeptides often present challenges because of their susceptibility to enzymatic degradation and relatively rapid clearance.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 was developed to address some of these limitations through albumin-binding technology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts design has been investigated in relation to:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePeptide stability\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAlbumin conjugation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eSystemic exposure\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eElimination half-life\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePharmacodynamic duration\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePeptide–protein interactions\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese properties make CJC-1295 an important example of long-acting peptide engineering.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 and Metabolic Research\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eThe growth hormone–IGF-1 axis participates in the regulation of several metabolic processes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGlucose metabolism\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eLipid metabolism\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eProtein turnover\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEnergy balance\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEndocrine signaling\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTissue growth and maintenance\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBecause CJC-1295 influences GH and IGF-1 concentrations in experimental human studies, it is relevant to investigations of endocrine metabolic pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, CJC-1295 has not been established as an effective or safe intervention for fat loss, metabolic optimization or muscle development.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch into hormonal responses should not be confused with demonstrated improvements in clinical outcomes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 and Skeletal Muscle Biology\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eGrowth hormone and IGF-1 participate in biological processes relevant to skeletal muscle physiology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese processes include cellular signaling, tissue maintenance and protein metabolism.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 may be of interest in experimental studies examining the relationship between the GH–IGF-1 axis and skeletal muscle biology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch topics include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGrowth hormone signaling\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIGF-1-associated pathways\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMuscle-cell biology\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eProtein metabolism\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEndocrine regulation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTissue adaptation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, published CJC-1295 studies measuring hormone concentrations do not establish that the compound increases muscle mass, strength or athletic performance in humans.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 and Body Composition Research\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eBody composition is influenced by numerous physiological systems, including nutritional status, physical activity, insulin signaling and endocrine regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eGrowth hormone has biological effects relevant to lipid metabolism and body composition.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 has consequently attracted interest in experimental research examining the GH–IGF-1 axis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, evidence demonstrating sustained hormone elevation is not equivalent to evidence of meaningful body-fat reduction or improved body composition.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eControlled clinical outcome studies would be required to establish such effects.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 should therefore not be presented as a clinically proven fat-loss or body-recomposition compound.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 and Sleep-Related Endocrine Research\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eGrowth hormone secretion exhibits relationships with sleep physiology, particularly slow-wave sleep.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis relationship has generated interest in the interaction between GHRH signaling and sleep-associated endocrine processes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 may be relevant to research investigating:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGH secretion patterns\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCircadian endocrine regulation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eSleep-associated hormone release\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eHypothalamic–pituitary signaling\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eNeuroendocrine feedback\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, there is insufficient clinical evidence to establish CJC-1295 as an effective treatment for insomnia, sleep quality or sleep-related disorders.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 and Aging Biology\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eGrowth hormone and IGF-1 signaling are frequently investigated in the context of aging biology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTheir activity changes throughout the lifespan and interacts with multiple metabolic and cellular pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 has attracted attention because of its ability to influence circulating GH and IGF-1 concentrations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, aging biology is complex.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHigher growth hormone or IGF-1 concentrations do not necessarily indicate healthier aging.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThere is no established clinical evidence that CJC-1295 reverses aging, extends human lifespan or prevents age-associated disease.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts relevance should be described as \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eendocrine and aging-related pathway research\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, rather than proven anti-aging activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 and GHRH Receptor Pharmacology\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eThe GHRH receptor belongs to the class B family of G protein-coupled receptors.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts activation initiates intracellular signaling associated with pituitary growth hormone release.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 research is relevant to understanding:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003ePeptide–receptor interactions\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eGHRH receptor agonism\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eGs protein signaling\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eAdenylyl cyclase activation\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003ecAMP signaling\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003ePituitary endocrine responses\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eReceptor stimulation duration\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eLong-acting peptide pharmacology\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThese mechanisms make CJC-1295 a useful subject for research into peptide-based endocrine signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 and Ipamorelin Research\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 is sometimes discussed alongside \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eipamorelin\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, a synthetic growth hormone secretagogue.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe two compounds have different principal receptor targets.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCJC-1295\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e acts through GHRH receptor-associated pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIpamorelin\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e acts primarily through the growth hormone secretagogue receptor, GHSR1a.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese receptor systems participate in the broader regulation of growth hormone secretion.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearchers may investigate interactions between GHRH-associated and ghrelin receptor-associated signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, the existence of complementary receptor pathways does not establish that combining the compounds is safe, clinically effective or beneficial.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePublished findings from CJC-1295 monotherapy studies should not be presented as evidence for the safety or efficacy of CJC-1295–ipamorelin combinations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 vs. Other GHRH-Related Peptides\u003c\/span\u003e\u003c\/h2\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003e\u003cspan\u003eCompound\u003c\/span\u003e\u003c\/th\u003e\n\u003cth\u003e\u003cspan\u003eClassification\u003c\/span\u003e\u003c\/th\u003e\n\u003cth\u003e\u003cspan\u003ePrincipal Research Feature\u003c\/span\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003eCJC-1295 With DAC\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eLong-acting GHRH analogue\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eAlbumin-binding technology\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003eModified GRF (1–29)\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eModified GHRH analogue\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eNo DAC component\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003eSermorelin\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eGHRH (1–29) analogue\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eGHRH receptor signaling\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003eTesamorelin\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eStabilized GHRH analogue\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eEndocrine and metabolic research\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan\u003eIpamorelin\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eGrowth hormone secretagogue\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eGHSR1a signaling\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cspan\u003eAlthough these compounds are associated with growth hormone regulation, they differ in molecular structure, receptor pharmacology, pharmacokinetics and clinical evidence.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThey should not be treated as interchangeable.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eSafety and Scientific Limitations\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 has demonstrated pharmacological activity in small human studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, the available clinical evidence is insufficient to establish long-term safety or therapeutic efficacy.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eImportant considerations include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eSustained GH and IGF-1 elevation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePotential effects on glucose regulation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFluid retention and other endocrine effects\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eUncertain long-term safety\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eLimited clinical outcome data\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eDifferences between research-grade and pharmaceutical formulations\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePotential product identity and purity concerns\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eChanges in the GH–IGF-1 axis may have consequences beyond the intended experimental endpoint.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTherefore, short-term tolerability findings should not be interpreted as proof of long-term safety.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 is not an approved general-purpose treatment for growth hormone enhancement, muscle development, weight management, recovery or longevity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003ePotential Research Applications\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 may be of interest in controlled scientific investigations involving:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGrowth hormone-releasing hormone biology\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGHRH receptor signaling\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePituitary function\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGrowth hormone secretion\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIGF-1 regulation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eHypothalamic–pituitary signaling\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eNeuroendocrine physiology\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eHormonal pulsatility\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEndocrine feedback\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePeptide pharmacokinetics\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAlbumin-binding peptide technology\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eDrug affinity complex research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePeptide–protein conjugation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ecAMP-associated signaling\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGrowth hormone-associated metabolism\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eSkeletal muscle endocrine biology\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAging-related endocrine pathways\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eExperimental peptide pharmacology\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eIts principal scientific significance lies in the investigation of prolonged GHRH receptor stimulation and the resulting endocrine responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eCJC-1295 Research Overview\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCompound Name:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e CJC-1295\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eClassification:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Synthetic GHRH Analogue\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eOriginal Research Form:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e CJC-1295 With DAC\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePrincipal Molecular Target:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Growth Hormone-Releasing Hormone Receptor (GHRHR)\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePrimary Research Pathway:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e GH–IGF-1 Axis\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePharmacological Feature:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Long-Acting Albumin Association\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePrimary Research Fields:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Endocrinology \/ Pituitary Signaling \/ Peptide Pharmacokinetics\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eClinical Status:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigational; no established approved therapeutic indication\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eProduct Information\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eProduct Name:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e CJC-1295\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eBrand:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e ICAME Pharmacy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eProduct Category:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Research Peptide\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eResearch Classification:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Growth Hormone-Releasing Hormone Analogue\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eResearch Area:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e GHRH Receptor Biology \/ Growth Hormone Signaling \/ IGF-1 Research\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIntended Use:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Laboratory Research \u0026amp; Development Only\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe exact identity of the supplied material must be verified before publication.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn particular, the product documentation should clearly establish whether the material is:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCJC-1295 With DAC\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eor\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eModified GRF (1–29), Commonly Marketed as CJC-1295 Without DAC\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese are distinct molecular entities.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBatch-specific documentation should include, where applicable:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eVerified peptide identity and sequence\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003ePresence or absence of DAC\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eChemical form and counterion\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eMolecular weight\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eAnalytical purity\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eAnalytical methodology\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eCertificate of Analysis (COA)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eBatch\/lot identification\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eValidated storage conditions\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eClaims about prolonged albumin binding and multi-day pharmacokinetics should not be applied to a no-DAC product.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eImportant Research Use Notice\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cspan\u003eFOR RESEARCH USE ONLY (RUO)\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eThis ICAME Pharmacy product is intended exclusively for legitimate \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003elaboratory, analytical and scientific research purposes\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eNot for human or veterinary use. Not for diagnostic, therapeutic, muscle-development, weight-management, hormone-enhancement, recovery, performance-enhancing or anti-aging purposes. Not for direct administration to humans or animals.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCJC-1295 is a pharmacologically active investigational peptide.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eClinical findings involving investigational pharmaceutical formulations should not be interpreted as evidence of safety, efficacy or pharmaceutical equivalence for ICAME Pharmacy research materials.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInformation presented on this page is intended solely for scientific and educational purposes and should not be interpreted as medical advice, prescribing information, dosage guidance or instructions for human use.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch2\u003e\u003cspan\u003eAbout ICAME Pharmacy\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eICAME Pharmacy\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e provides specialized research products for professional laboratory and scientific applications.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOur portfolio focuses on compounds relevant to contemporary areas of \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003epeptide science, molecular biology, endocrinology, receptor pharmacology, metabolic research and experimental life sciences\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eProduct information is presented with an emphasis on responsible research use, scientific transparency, clear product identification and professional research applications.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFor batch-specific documentation, analytical information and product inquiries, please contact \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eICAME Pharmacy\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"icamepharmacy","offers":[{"title":"Default Title","offer_id":52935145750839,"sku":null,"price":50.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0986\/5458\/5143\/files\/cjc-1295-5mg.jpg?v=1790247899","url":"https:\/\/icamepharmacy.com\/products\/cjc-1295","provider":"Icame Pharmacy","version":"1.0","type":"link"}